Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for TOLBUTAMIDE
- Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide
- Phenotyping of High Dose Rifampicin
- Licorice Botanical Dietary Supplements - Metabolism and Safety in Women
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
- Drug Interaction Study of CT1812 in Healthy Volunteers
- Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s
- Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
- A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers
- Dicloxacillin: Clinical Relevance of Drug-drug Interactions by Induction of Drug Metabolism.
- An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates
- Incretin-based Drugs and Acute Pancreatitis
- Incretin-based Drugs and Pancreatic Cancer
- A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SU
- Incretin-based Drugs and the Risk of Heart Failure
- Evaluation of CYP450 Activities in Diabetic Patients vs. Non-diabetic Subjects
- A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates
- Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study
- Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers
- Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
- Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.
- Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors
- A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma
- A Pharmacokinetic and Drug Interaction Study of JNJ-26489112 in Healthy Volunteers
- AZD2066 Cocktail Study
- Variation in Sulphonylurea Response in Type 2 Diabetes
- Ocsaar and CYP2C9 Ploymorphism, Is There a Connection Between Pharmacokinetics, Pharmacodynamics and Pharmacogenetics?
- A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.
- Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics
- Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between CYP2C9 Inhibitor and Substrate
- Increased Gluconeogenesis is One Cause of Cystic Fibrosis Related Diabetes (CFRD)
Clinical trials list
click for details